A combination of the HER2 agent, called disitamab vedotin, and Junshi Biosciences’ PD-1 inhibitor toripalimab outperformed ...

Pfizer’s first-quarter revenue missed analyst estimates as it faces an “uncertain and volatile external environment.” ...

We expect Pfizer’s several newly launched drugs, like the Velsipity pill for ulcerative colitis, the pentavalent meningococcal vaccine Penbraya, and new gene therapies for hemophilia ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Pfizer will halt its development of a weight-loss drug that was being closely watched by investors, in a ...

Pfizer did achieve its goal of converting danuglipron into a once-daily formulation, which could imply that its new formulation technology could be applied to other drug candidates. Pfizer has up ...

That decline was only partly offset by Comirnaty, Pfizer's COVID vaccine co-developed with BioNTech, which generated $565 million and outpaced the $325.5 million estimate. Sales of flagship drug ...